Crystals in cytarabine prompt warning
- PDF / 122,700 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 107 Downloads / 181 Views
1
Crystals in cytarabine prompt warning Hospira, in conjunction with Health Canada, is highlighting the potential for cytarabine crystallisation in specific lots of the company’s Cytarabine Injection 2g/20mL (100 mg/mL) product. In a "Dear Healthcare Professional" letter, the company explains that cytarabine crystallisation has been reported outside of Canada. No adverse events have been reported in connection with this crystallisation issue. Investigations revealed that the crystals were particles of the active pharmaceutical ingredient. Hospira has taken corrective action to resolve this issue for future lots of Cytarabine Injection. The letter notes that hospital pharmacists and those involved in preparing Cytarabine Injection for administration must inspect the cytarabine vial for signs of crystallisation. The product should not be used if crystals are found on inspection. The letter also warns against using a filter needle or filter set to prepare or administer Cytarabine Injection which contains crystals. Health Canada. Health Canada Endorsed Important Safety Information on Cytarabine Injection in 2 g/ 20 mL (100mg/mL). Internet Document : 6 May 803054405 2011
0114-9954/10/1352-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Reactions 21 May 2011 No. 1352
Data Loading...
